Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up

J Inherit Metab Dis. 2009 Dec:32 Suppl 1:S5-10. doi: 10.1007/s10545-008-1009-4. Epub 2009 Jan 7.

Abstract

Sepiapterin reductase (SR) catalyses the last step in the tetrahydrobiopterin biosynthesis pathway; it converts 6-pyruvoyl-tetrahydropterin (6-PTP) to BH(4) in an NADPH-dependent reaction. SR deficiency is a very rare autosomal recessive disorder with normal phenylalanine (Phe) concentration in blood and diagnostic abnormalities are detected in CSF. We present a 16-month-old girl with SR deficiency. From the newborn period she presented with an adaptation regulatory disorder. At the age of 3 months, abnormal eye movements with dystonic signs and at 4.5 months psychomotor retardation were noticed. Since that time axial hypotonia with limb spasticity (or rather delayed reflex development), gastro-oesophageal reflux and fatigue at the end of the day has been observed. Brain MRI was normal; EEG was without epileptiform discharges. Analysis of biogenic amine metabolites in CSF at the age of 16 months showed very low HVA and 5-HIAA concentrations. Analysis of CSF pterins revealed strongly elevated dihydrobiopterin (BH(2)), slightly elevated neopterin and elevated sepiapterin levels. Plasma and CSF amino acids concentrations were normal. A phenylalanine loading test showed increased Phe after 1 h, 2 h and 4 h and very high Phe/Tyr ratios. SR deficiency was confirmed in fibroblasts and a novel homozygous g.1330C>G (p.N127K) SPR mutation was identified. On L-dopa and then additionally 5-hydroxytryptophan, the girl showed slow but remarkable progress in motor and intellectual ability. Now, at the age of 3 years, she is able to sit; expressive speech is delayed (to 1 1/2 years), passive speech is well developed. Her visual-motor skills, eye-hand coordination and social development correspond to the age of 2 1/2 years.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5-Hydroxytryptophan / therapeutic use
  • Alcohol Oxidoreductases / deficiency*
  • Alcohol Oxidoreductases / genetics
  • Biogenic Amines / metabolism
  • Child, Preschool
  • Dystonia / drug therapy*
  • Dystonia / enzymology
  • Dystonia / psychology
  • Female
  • Follow-Up Studies
  • Homozygote
  • Humans
  • Levodopa / therapeutic use
  • Metabolism, Inborn Errors / drug therapy*
  • Metabolism, Inborn Errors / enzymology
  • Metabolism, Inborn Errors / psychology
  • Mutation, Missense
  • Psychomotor Disorders / drug therapy*
  • Psychomotor Disorders / enzymology
  • Psychomotor Disorders / psychology

Substances

  • Biogenic Amines
  • Levodopa
  • 5-Hydroxytryptophan
  • Alcohol Oxidoreductases
  • sepiapterin reductase

Supplementary concepts

  • Dystonia, Dopa-Responsive, due to Sepiapterin Reductase Deficiency